Katsumata Y, Inoue E, Harigai M, et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis. 2024 Jul 15;83(8):998-1005. PMID: 38423757.
Babalola KT, Arora M, Ganugula R,et al. Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes. Pharmacol Rev. 2024 Feb 13;76(2):228-250 PMID: 38351070
Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med. 1979 Feb;66(2):210-5. PMID: 218447.
Steiman AJ, Gladman DD, Ibañez D,et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken). 2012 Apr;64(4):511-8. PMID: 22162433.
Huang H, Mu L, Zhang Z, et al. Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. Arthritis Res Ther. 2021 Oct 29;23(1):275. PMID: 34715915;
Touma Z, Gladman DD, Su J, et al. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. PMID: 29688532.
Ji L, Xie W, Fasano S et al. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. Lupus Sci Med. 2022 Jan;9(1):e000603. PMID: 34996857.
Ji L, Xie W, Zhang Z. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford). 2021 Dec 1;60(12):5517-5526. PMID: 33576768.
Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. PMID: 33971155.
Therneau, T. M., & Grambsch, P. M. (2000)"Modeling Survival Data: Extending the Cox Model"Springer
